Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: disruptive technology

Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity enhancement properties of its combinatorial regenerative biologic candidates.

“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”

Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.

The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.

“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival, developing a broad understanding of the combinatorial biochemical approaches they use to control nested hierarchies of disease (i.e. gene, cell, tissue, organism, environment),” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This research initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

“Two Tesla Motors veterans want to build a European counterpart to Elon Musk’s “gigafactory”, in an effort to stake out a dominant position in the fast-evolving supply chain for makers of electric vehicles.”

Read more

Superlubricity nano-structured self-assembling coating repairs surface wear, decreases emissions and increases HP and gas mileage.

Globally about 15 percent of manmade carbon dioxide comes from vehicles. In more developed countries, cars, trucks, airplanes, ships and other vehicles account for a third of emissions related to climate change. Emissions standards are fueling the lubricant additives market with innovation.

Up to 33% of fuel energy in vehicles is used to overcome friction. Tribology is the science of interacting surfaces in relative motion inclusive of friction, wear and lubrication. This is where TriboTEX, a nanotechnology startup is changing the game of friction modification and wear resilience with a lubricant additive that forms a nano-structured coating on metal alloys.

This nano-structured coating increases operating efficiency and component longevity. It is comprised of synthetic magnesium silicon hydroxide nanoparticles that self-assemble as an ultralow friction layer, 1/10 of the original friction resistance. The coating is self-repairing during operation, environmentally inert and extracts carbon from the oil. The carbon diamond-like nano-particle lowers the friction budget of the motor, improving fuel economy and emissions in parallel while increasing the power and longevity of the motor.

TriboTEX has a Kickstarter campaign that has just surpassed $100,000 in funding. The early bird round has just closed that offered the product at one half the cost of its retail. The final round offers the lubricant system self-forming coating at 75 percent and is ending shortly. The founder Dr. Pavlo Rudenko, Ph.D. is a graduate of Singularity University GSP11 program.

I use to hate it when my dad insisted that I read something longer than 2 paragraphs. (Something related to his interests, but not to my school work, his career or our family). That’s because it shouldn’t require a 30 minute read to determine if it piques my interest, as it does his.

But I am asking Lifeboat readers to invest 37 minutes in the video linked below. Even if you give it just 5 minutes, it will provide sufficient motive for you to stick around until the end. [continue below video]

I want you view it because we are on the threshold of something bigger than many people realize. Bitcoin and the blockchain is not just a new currency or a way of distributing books among network users. We are becoming involved with a radical experiment in applied game theory that is shockingly simple, but nascent. Opportunities abound, and the individuals who recognize those opportunities or learn to exploit them will benefit themselves as they benefit the global community. Because it is so radical (and because it clashes with deeply ingrained beliefs about authority, control mechanisms, democracy and money), it seems complex and risky—but it’s really not.

I am a Bitcoin educator and columnist. I have taught college seminars in Bitcoin and I will be keynote speaker at the 2017 Digital Currency Summit in Johannesburg. I design online courses for the most popular cryptocurrency self-learning groups. But Antonopolous runs circles around me. He is a Bitcoin evangelist extraordinaire. All of his presentations are superb, but this one provides context. It conveys an understanding that Bitcoin novices and professionals equally appreciate. It answers questions the viewer hadn’t asked, but would have.

There are hundreds of videos and PowerPoint presentations that explain how Bitcoin works. But they rarely provide context. Few of them convey why it is such an important development and why it has overtaken biotech & pharmaceuticals as the focus of VCs . Few can explain why an ethereal Bitcoin (a unit that you cannot hold) has just surpassed the value of a unit of gold. And few people realize that volatility has been abating as the increase in value and adoption is surging.

As you watch Antonopolous, you are certain to think about things that you did not previously know—or at least, that you did not reflect upon. My purpose in asking you to view it, is not to sell you on Bitcoin or the blockchain, but to provide the context that may help you to code, consult, write articles, teach, begin trading, start saving, and more.

Philip Raymond co-chairs Crypsa & Bitcoin Event, columnist & board member at Lifeboat, editor
at WildDuck and will deliver the keynote address at Digital Currency Summit in Johannesburg.

Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm

Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.

“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”

HIV-1 infection afflicts more than 35 million people worldwide. For individuals who have access to antiretroviral therapy, these drugs can effectively suppress, but not cure, HIV-1 infection. The only documented case for an HIV/AIDS cure was a patient with HIV-1 and acute myeloid leukemia who received allogeneic hematopoietic cell transplantation from a graft that carried the HIV-resistant CCR5-Delta32 homozygous mutation. The patient has remained without any evidence of HIV infection for more than 8 years after discontinuation of antiretroviral drug therapy.

However, identifying immune matched adult CCR5- Delta32 homozygous donors for a given patients is not readily feasible in part because the prevalence is in only about 0.8%–1% of individuals of northern European descent and much less in other ethnic groups, as well as the fact that for such transplants with adult cells there needs to be a very close HLA match between donor and patient.

In contrast, cord blood that is CCR5- Delta32 homozygous provides a major advantage in that much less stringent HLA matching is required between donor and patient. However, a technological method to cost effectively and industrially scale the production of such cells has been missing.

“We look forward to working closely with Bioquark Inc. on this exciting initiative,” said Mr. Paul Collier, Managing Director of SC21 Biotech. “The ability to apply Bioquark’s cellular reprogramming tools in order to produce industrial quantities of such precious cell lines will offer a much greater global penetration of this important therapeutic modality for HIV.”

“Bioquark has spent several years studying the evolutionarily perfected ability of bioactive moieties found in ooplasms to turn back biological time and re-set cellular regulatory state” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This unique initiative is one more step in our broad translation of such natural capabilities to control the progression of human diseases.”

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

About SC21 Biotech

SC21 Biotech is a novel a biotechnology company focused on translational therapeutic applications, as well as expedited, experimental access for “no option” patients, to a novel range of regenerative and reparative biomedical products and services, with the goal of reducing human degeneration, suffering, and death.

Research can seem bland to us laypersons. But, Marko Vukolić shares many of my research interests and he exceeds my academic credentials (with just enough overlap for me to understand his work). So, in my opinion, his writing is anything but bland…

Vukolić started his career as a post-doc intern at IBM in Zurich Switzerland. After a teaching stint as assistant professor at Eurecom and visiting professor at ETH Zurich, he rejoined the IBM research staff in both cloud computing infrastructure and the Blockchain Group.*

As a researcher and academic, Vukolić is a rising star in consensus-based mechanisms and low latency replicated state machines. At Institut Mines-Télécom in Paris, he wrote papers and participated in research projects on fault tolerance, scalability, cloud computing and distributed trust mechanisms.

Now, at IBM Zurich, Vukolić has published a superior analysis addressing the first and biggest elephant in the Bitcoin ballroom, Each elephant addresses an urgent need:

  • Scalability & throughput
  • Incentivize (as mining reward withers)
  • Grow & diversify governance & geographic influence
  • Anonymize transactions to protect privacy
  • Recognize & preserve ownership

Regarding the first elephant, scalability, Bitcoin urgently needs to grow its Blockchain dynamics into something that is living and manageable. To that end, Vukolić refers to a transaction bookkeeping mechanism that works as a “fabric”. That is, it does not require every miner to access the history-of-the-world and append each transaction onto the same chain in serial fashion. Rather than growing an ever bigger blockchain—with ever bigger computers—we need a more 3D approach that uses relational databases in a multi-threaded, transactional environment, while still preserving the distributed, p2p trust mechanisms of the original blockchain.

While clearly technical, it is a good read, even for lay enthusiasts. It directly relates to one of the elephants in the room.

I have pasted Marko’s Abstract below. The full paper is 10½ pages (14 with references).

Bitcoin cryptocurrency demonstrated the utility of global consensus across thousands of nodes, changing the world of digital transactions forever. In the early days of Bitcoin, the performance of its probabilistic proof-of-work (PoW) based consensus fabric, also known as blockchain, was not a major issue. Bitcoin became a success story, despite its consensus latencies on the order of an hour and the theoretical peak throughput of only up to 7 transactions per second.

The situation today is radically different and the poor performance scalability of early PoW blockchains no longer makes sense. Specifically, the trend of modern cryptocurrency platforms, such as Ethereum, is to support execution of arbitrary distributed applications on blockchain fabric, needing much better performance. This approach, however, makes cryptocurrency platforms step away from their original purpose and enter the domain of database-replication protocols, notably, the classical state-machine replication, and in particular its Byzantine fault-tolerant (BFT) variants.

In this paper, we contrast PoW-based blockchains to those based on BFT state machine replication, focusing on their scalability limits. We also discuss recent proposals to overcoming these scalability limits and outline key outstanding open problems in the quest for the “ultimate” blockchain fabric(s). Keywords: Bitcoin, blockchain, Byzantine fault tolerance, consensus, proof-of-work, scalability, state machine replication

* Like Marko, Blockchains, Cloud computing, and Privacy are, also my primary reserach interests, (GMTA!). But, I cede the rigorous, academic credentials to Marko.

† BFT = Byzantine Fault Tolerant consensus protocols

Related—and recently in the news:

Raymond co-chairs CRYPSA and The Bitcoin Event. A columnist & board member at Lifeboat Foundation
he edits AWildDuck. He will deliver the keynote address at Digital Currency Summit in Johannesburg.

Recent evidence suggests that a variety of organisms may harness some of the unique features of quantum mechanics to gain a biological advantage. These features go beyond trivial quantum effects and may include harnessing quantum coherence on physiologically important timescales.

Quantum Biology — Quantum Mind Theory

Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine food ingredients in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.

green-cell

“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine food ingredients, including functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”

Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.

gene-sequencing

The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome and virome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.

“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival,” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This Eurasian initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease and degeneration.”

bqaproduction

About Bioquark, Inc.

Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.

Link to Press — http://www.prweb.com/releases/2017/01/prweb13955162.htm

Bioquark Inc. (www.bioquark.com) Interview in MoneyWeek

bioquarklogo

Read whole story: http://moneyweek.com/who-wants-to-live-forever/

Bioquark Inc. (www.bioquark.com) mention on CNBC — the best way to make chemo easier is to eliminate the need for it forever!
recovering patient